AMANTADINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Amantadine Hydrochloride, and when can generic versions of Amantadine Hydrochloride launch?
Amantadine Hydrochloride is a drug marketed by Actavis Elizabeth, Alembic, Bionpharma, Chartwell Molecular, Heritage Pharma, Humanwell Puracap, Invagen Pharms, Rising, Rubicon, Sandoz, Strides Pharma, Upsher Smith Labs, Watson Labs, Watson Labs Inc, Zydus Pharms, Aurobindo Pharma Usa, Chartwell Rx, Cmp Pharma Inc, Elysium, G And W Labs Inc, Genus, Pharm Assoc, Teva Pharms, Vintage, Xttrium Labs Inc, Athem, Edenbridge Pharms, and Jubilant Generics. and is included in thirty-four NDAs.
The generic ingredient in AMANTADINE HYDROCHLORIDE is amantadine hydrochloride. There are seven drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the amantadine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Amantadine Hydrochloride
A generic version of AMANTADINE HYDROCHLORIDE was approved as amantadine hydrochloride by UPSHER SMITH LABS on August 5th, 1986.
Summary for AMANTADINE HYDROCHLORIDE
Recent Clinical Trials for AMANTADINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Shahid Beheshti University of Medical Sciences | Phase 2 |
| Hospital San Carlos, Madrid | Phase 3 |
| University Hospital Tuebingen | Phase 2 |
Pharmacology for AMANTADINE HYDROCHLORIDE
| Drug Class | Influenza A M2 Protein Inhibitor |
| Mechanism of Action | M2 Protein Inhibitors |
Medical Subject Heading (MeSH) Categories for AMANTADINE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for AMANTADINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for AMANTADINE HYDROCHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| GOCOVRI | Extended-release Capsules | amantadine hydrochloride | 68.5 mg | 208944 | 1 | 2020-04-30 |
| GOCOVRI | Extended-release Capsules | amantadine hydrochloride | 137 mg | 208944 | 1 | 2018-01-16 |
US Patents and Regulatory Information for AMANTADINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strides Pharma | AMANTADINE HYDROCHLORIDE | amantadine hydrochloride | TABLET;ORAL | 209035-001 | Jun 9, 2017 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Athem | AMANTADINE HYDROCHLORIDE | amantadine hydrochloride | TABLET;ORAL | 210215-001 | Mar 10, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Upsher Smith Labs | AMANTADINE HYDROCHLORIDE | amantadine hydrochloride | TABLET;ORAL | 076186-001 | Dec 16, 2002 | AB | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
